Public Employees Retirement System of Ohio lowered its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 3.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 96,767 shares of the company’s stock after selling 3,042 shares during the period. Public Employees Retirement System of Ohio’s holdings in Cencora were worth $21,780,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Lake Street Advisors Group LLC raised its holdings in Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after buying an additional 43 shares in the last quarter. Financial Advocates Investment Management raised its stake in shares of Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after acquiring an additional 44 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after purchasing an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its position in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after purchasing an additional 46 shares during the period. Finally, Checchi Capital Advisers LLC raised its position in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after purchasing an additional 48 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 93,018 shares of company stock valued at $22,478,942 over the last quarter. Corporate insiders own 15.80% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Cencora
Cencora Stock Down 1.5 %
Shares of COR stock opened at $236.94 on Wednesday. Cencora, Inc. has a one year low of $195.83 and a one year high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a fifty day moving average price of $237.68 and a 200 day moving average price of $233.85. The stock has a market cap of $45.80 billion, a P/E ratio of 31.55, a price-to-earnings-growth ratio of 1.62 and a beta of 0.45.
Cencora Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.93%. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is 29.29%.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
- Five stocks we like better than Cencora
- Why Invest in 5G? How to Invest in 5G Stocks
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Best Stocks Under $5.00
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- ETF Screener: Uses and Step-by-Step Guide
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.